AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Market Closed 06-05 16:00:00 EDT

5.62

-0.75

-11.77%

盘后5.77

+0.15+2.67%

19:58 EDT

High6.33	Low5.50	Vol8.93M
Open6.20	D1 Closing6.37	Amplitude13.03%
Mkt Cap1.72B	Tradable Cap1.14B	Total Shares305.26M
T/O51.88M	T/O Rate4.40%	Tradable Shares202.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":5.62,"timestamp":1780689600000,"preClose":6.37,"halted":0,"volume":8927909,"hourTrading":{"tag":"盘后","latestPrice":5.77,"preClose":5.62,"latestTime":"19:58 EDT","volume":532900,"amount":2998601.8123,"timestamp":1780703918623,"change":0.15,"changeRate":0.02669,"amplitude":0.049822},"delay":0,"changeRate":-0.11773940345368916,"floatShares":202749853,"shares":305264947,"eps":-0.480392,"marketStatus":"Market Closed","change":-0.75,"latestTime":"06-05 16:00:00 EDT","open":6.2,"high":6.33,"low":5.5,"amount":51875999.144587,"amplitude":0.130298,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.480392,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":7,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":6.37,"preHourTrading":{"tag":"盘前","latestPrice":6.1801,"preClose":6.37,"latestTime":"09:29 EDT","volume":44477,"amount":280057.4585985,"timestamp":1780666152171,"change":-0.1899,"changeRate":-0.029812,"amplitude":0.032967},"postHourTrading":{"tag":"盘后","latestPrice":5.77,"preClose":5.62,"latestTime":"19:58 EDT","volume":532900,"amount":2998601.8123,"timestamp":1780703918623,"change":0.15,"changeRate":0.02669,"amplitude":0.049822},"volumeRatio":0.9789253899395928,"impliedVol":0.9429,"impliedVolPercentile":0.3466},"requestUrl":"/m/hq/s/ABCL/wiki","defaultTab":"wiki","newsList":[{"id":"2641141474","title":"AbCellera Biologics Adds Victor Sandor to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2641141474","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641141474?lang=en_us&edition=fundamental","pubTime":"2026-06-06 00:30","pubTimestamp":1780677056,"startTime":"0","endTime":"0","summary":"AbCellera Biologics ( ($ABCL) ) just unveiled an announcement. On June 1, 2026, AbCellera Biologics appointed medical oncologist Victor Sandor to i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-adds-victor-sandor-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-adds-victor-sandor-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641143339","title":"AbCellera appoints Victor Sandor to board as independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2641143339","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641143339?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:00","pubTimestamp":1780664450,"startTime":"0","endTime":"0","summary":"AbCellera appointed Victor Sandor, M.D.C.M., to its board as an independent director.Sandor was chief medical officer at Array BioPharma before its acquisition by Pfizer.He previously led global clinical development at Incyte, supporting the approval of Jakafi .Sandor also held senior oncology roles at Biogen, with earlier positions at AstraZeneca.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire  on June 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL5PhjlM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641143888","title":"Abcellera Appoints DR. Victor Sandor to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641143888","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641143888?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:00","pubTimestamp":1780664401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nTUAB6BZH2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640186611","title":"Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640186611","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640186611?lang=en_us&edition=fundamental","pubTime":"2026-06-04 01:21","pubTimestamp":1780507263,"startTime":"0","endTime":"0","summary":"In recent months, AbCellera Biologics Inc. has seen analyst earnings estimates for the full year rise meaningfully, while its performance has surpassed the broader Medical sector and its Medical – Biomedical and Genetics peers.\nThis combination of a stronger earnings outlook and relative industry outperformance has drawn increased attention to AbCellera’s evolving business model and profit potential.\nWe’ll now examine how this stronger earnings outlook could influence AbCellera’s existing...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/is-abcellera-abcl-turning-upgraded-earnings-forecasts-into-a","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/is-abcellera-abcl-turning-upgraded-earnings-forecasts-into-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911809","title":"A Look At AbCellera Biologics (ABCL) Valuation After Improved Earnings Outlook And Sector Outperformance","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911809","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640911809?lang=en_us&edition=fundamental","pubTime":"2026-06-02 17:16","pubTimestamp":1780391807,"startTime":"0","endTime":"0","summary":"Recent analyst reports highlight a more positive earnings outlook for AbCellera Biologics (ABCL). This coincides with the stock outperforming the broader Medical sector and its peers this year, which has influenced sentiment around its recent move.\nSee our latest analysis for AbCellera Biologics.\nThe recent 1 month share price return of 45.82% and 90 day share price return of 74.12% suggest momentum has been building, even though the 3 year total shareholder return is slightly down while the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-improved","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-improved","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637950319","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637950319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637950319?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:40","pubTimestamp":1779450047,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-abcellera-biologics-abcl-and-indivior-indv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-hims-hers-health-hims-abcellera-biologics-abcl-and-indivior-indv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL","BK4121","HIMS","HIMZ","BK4535","HIYY","HIMY","BK4007","BK4196","HMYY","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636731865","title":"AbCellera publishes corporate overview on internal antibody pipeline, platform expansion strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636731865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636731865?lang=en_us&edition=fundamental","pubTime":"2026-05-20 02:01","pubTimestamp":1779213675,"startTime":"0","endTime":"0","summary":"AbCellera outlined a strategy shift toward advancing an internal pipeline of antibody medicines, supported by an integrated platform spanning discovery through clinical manufacturing and development.The company cited 20+ internal program starts, with 2 molecules in IND-enabling activities and 2 molecules in the clinic as of March 31, 2026.ABCL635, an NK3R-targeting GPCR antibody for moderate-to-severe menopausal vasomotor symptoms, is in Phase 2 with a topline readout expected in Q3 2026.ABCL575, an OX40L program in immunology and inflammation, is in Phase 1 with a topline readout expected in Q4 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL3K50px:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636070851","title":"AbCellera director John S. Montalbano acquires 20,000 common shares for $95,400","url":"https://stock-news.laohu8.com/highlight/detail?id=2636070851","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636070851?lang=en_us&edition=fundamental","pubTime":"2026-05-19 00:10","pubTimestamp":1779120638,"startTime":"0","endTime":"0","summary":"Abcellera Biologics director John S. Montalbano bought 20,000 common shares at USD 4.77.Directly held stake rose to 241,000 common shares.He also reported 5,000 common shares held indirectly by his spouse.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL3t4rHh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","ABCL","LU0353189680.USD","LU0353189763.USD","LU2087625088.SGD","BK4209","BK4121","BK4535","PZZA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635543273","title":"AbCellera Biologics (ABCL) Q4 Revenue Surge Tests High 20.1x P/S Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2635543273","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635543273?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:55","pubTimestamp":1778633759,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (NasdaqGS:ABCL) opened its Q1 2026 reporting season with recent quarterly revenue figures of US$44.9 million in Q4 2025 and a reported loss of US$8.9 million. This equates to basic EPS of US$0.03. On a trailing 12 month basis, revenue sits at US$75.1 million with EPS at US$0.49 and net income losses of US$146.4 million. Over the past year, the company has seen quarterly revenue move between US$4.2 million and US$44.9 million alongside quarterly EPS ranging from US$0.03 to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-biologics-abcl-q4-revenue-surge-tests-high-201x-ps","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-biologics-abcl-q4-revenue-surge-tests-high-201x-ps","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635722489","title":"AbCellera Biologics Bets Big on 2026 Trial Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722489","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635722489?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:11","pubTimestamp":1778631076,"startTime":"0","endTime":"0","summary":"Abcellera Biologics, Inc. (($ABCL)) has held its Q1 earnings call. Read on for the main highlights of the call. AbCellera Biologics’ latest earning...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-bets-big-on-2026-trial-catalysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-bets-big-on-2026-trial-catalysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103494780","title":"Stock Track | AbCellera Biologics Plummets 11.65% Intraday Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1103494780","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103494780?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:45","pubTimestamp":1778593550,"startTime":"0","endTime":"0","summary":"AbCellera Biologics' stock plummeted 11.65% during intraday trading on Tuesday, extending significant pre-market losses.The sharp decline follows the release of the company's first-quarter 2026...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634321576","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), CVRx (CVRX) and AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634321576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634321576?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:40","pubTimestamp":1778586040,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on West Pharmaceutical Services (WST), CVRx (CVRX) and AbCellera Bio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-west-pharmaceutical-services-wst-cvrx-cvrx-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-west-pharmaceutical-services-wst-cvrx-cvrx-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B64QTZ34.USD","LU0012050646.USD","LU0345774631.USD","LU0106261612.USD","BK4581","BK4535","CVRX","WST","BK4588","BK4121","IE00BFXG0V08.USD","ABCL","LU0029874061.USD","LU0128526141.USD","HCSG","BK4539","BK4082","LU0345774391.USD","BK4585","XLV","BK4137","BK4504","BK4567","IE00BYQQ9H92.USD","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120440302","title":"Stock Track | AbCellera Biologics Plunges 5.47% in Pre-Market Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1120440302","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120440302?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:21","pubTimestamp":1778574101,"startTime":"0","endTime":"0","summary":"AbCellera Biologics' stock experienced a pre-market plunge of 5.47% on Tuesday, extending losses following the release of its first-quarter 2026 financial results.Despite beating analyst expectations...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634522792","title":"Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634522792","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634522792?lang=en_us&edition=fundamental","pubTime":"2026-05-12 09:30","pubTimestamp":1778549450,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ceribell-inc-cbll-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ceribell-inc-cbll-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4588","LABU","CBLL","LU0029874061.USD","BK4137","BK4535","BK4121","BK4585","LU0128526141.USD","XLV","BK4581","BK4082","ABCL","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176683870","title":"Stock Track | AbCellera Biologics Plunges 7.24% Post-Market Despite Q1 Beat as Investors Focus on Continued Losses and Rising R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=1176683870","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176683870?lang=en_us&edition=fundamental","pubTime":"2026-05-12 08:06","pubTimestamp":1778544362,"startTime":"0","endTime":"0","summary":"AbCellera Biologics' stock experienced a significant 7.24% plunge in post-market trading on Monday. The biotechnology company had just released its first-quarter 2026 financial results.Despite...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634553502","title":"AbCellera Biologics options imply 9.7% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2634553502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634553502?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:58","pubTimestamp":1778536720,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in AbCellera (ABCL) Biologics is 4.7x normal with calls leading puts 5:3. Implied volatility suggests the market is ant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-options-imply-9-7-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-options-imply-9-7-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141369593","title":"Stock Track | AbCellera Biologics Plunges 6.48% After-Hours Despite Beating Q1 Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=1141369593","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141369593?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:30","pubTimestamp":1778535048,"startTime":"0","endTime":"0","summary":"AbCellera Biologics' stock experienced a significant after-hours plunge of 6.48% following the release of its first-quarter 2026 financial results.The company reported a net loss of $43.2 million for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124577415","title":"Stock Track | AbCellera Biologics Soars 7.62% After-Hours on Earnings Beat and Positive Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1124577415","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124577415?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:45","pubTimestamp":1778532311,"startTime":"0","endTime":"0","summary":"AbCellera Biologics' stock surged 7.62% in the after-hours session following the release of its first-quarter 2026 financial results and an update on its clinical pipeline.The biotechnology company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634209230","title":"Earnings Flash (ABCL) AbCellera Biologics Posts Q1 Per Share Loss of $0.14, vs. FactSet Est Loss $0.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2634209230","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634209230?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:39","pubTimestamp":1778531950,"startTime":"0","endTime":"0","summary":"Earnings Flash (ABCL) AbCellera Biologics Posts Q1 Per Share Loss of $0.14, vs. FactSet Est Loss $0.17","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634302052","title":"AbCellera Biologics Q1 Loss Narrows, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2634302052","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634302052?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:39","pubTimestamp":1778531947,"startTime":"0","endTime":"0","summary":"AbCellera Biologics  reported Monday Q1 loss of $0.14 per diluted share, compared with a loss of $0.15 a year earlier.Analysts polled by FactSet expected loss of $0.17.Revenue for the quarter ended March 31 was $8.3 million, up from $4.2 million a year ago.Analysts surveyed by FactSet expected $5.9 million.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":-0.0891},{"period":"1month","weight":0.1151},{"period":"3month","weight":0.629},{"period":"6month","weight":0.5787},{"period":"1year","weight":1.3713},{"period":"ytd","weight":0.6433}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.002724},{"month":2,"riseRate":0,"avgChangeRate":-0.119779},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.059327},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.055905},{"month":5,"riseRate":0.666667,"avgChangeRate":0.054331},{"month":6,"riseRate":0.333333,"avgChangeRate":0.084738},{"month":7,"riseRate":0.6,"avgChangeRate":0.046684},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080936},{"month":9,"riseRate":0.6,"avgChangeRate":0.036664},{"month":10,"riseRate":0.6,"avgChangeRate":0.00539},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}